AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05875090 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma Screening
Description: Non-invasive diagnostic techniques will screen subjects in primary care setting for the existence of Glaucoma and categorised them in a binary system: referrable vs non-referrable to a Hospital-based Glaucoma Clinic
Study NCT05747781 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pilot Phase: standardized behavioral task
Description: Pilot Phase:~* Mobility under variable light conditions (scotopic, photopic, glare, dark adaptation), performed in a virtual environment.~* Visual search for objects in real life scenes (office, kitchen, living room) performed in a virtual environment.~* Ability to drive (UFOV and DVFAT psychophysical tests).
Study NCT05747781 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Validation Phase: standardized behavioral task
Description: Validation Phase:~* Mobility in variable light conditions (photopic and scotopic), performed in real and virtual environments.~* Visual search for objects in real scenes (office, kitchen, bedroom, living room) performed in a virtual environment.~* Driving ability (two psychophysical tests UFOV and DVFAT, one supervised road test).
Study NCT05392998 — intervention group
Intervention type: DEVICE
Intervention: Cataract surgery with Vivity intraocular lens implantation
Description: Cataract surgery with Vivity intraocular lens implantation
Study NCT06141486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MRI contrast-enhancing agents
Description: IV, as per respective label
Study NCT05655520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: Oral softgel lipid capsules
Study NCT06413524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body Vibration Therapy
Description: Each session includes six series, each lasting 2 minutes, with a frequency of 35 Hz and an amplitude of 2 mm, with a 60-second rest interval between series. For the starting position, the patient stands relaxed on the platform, holding the WBV platform handles.
Study NCT06413524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Local Vibration Therapy
Description: Each session includes six series, each lasting 2 minutes, with a frequency of 35 Hz and an amplitude of 2 mm, with a 60-second rest interval between series. After the warm-up exercise, the researcher helps the patient wear the localized vibration instrument. During the vibration, participants will hold onto the handle to ensure balance stability.
Study NCT06121297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CABA-201
Description: Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Study NCT05841407 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High nitrate isotonic drink
Description: High nitrate (12.9 mmol) drink with carbohydrate and minerals
Study NCT05841407 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: No nitrate isotonic drink
Description: Carbohydrate and mineral isotonic drink
Study NCT05430555 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR
Description: Single-dose intravenous infusion of MAGE-A1 directed TCR-transgenic T cells following a conditioning chemotherapy
Study NCT05702229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion
Study NCT05781347 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stretta
Description: Stretta is a FDA approved device for the management of GERD.
Study NCT05702229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: an anti PD-1 and anti CTLA-4 bispecific antibody; IV infusion
Study NCT05702229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: 5-fluorouracil 400 mg/m\^2 IV, oxaliplatin 85 mg/m\^2, leucovorin 400 mg/m\^2 (or levoleucovorin 200 mg/m\^2 when locally preferred and available), day 1, 5-fluorouracil 1200 mg/m\^2 IV 24 h day 1-2
Study NCT05702229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: capecitabine 1000 mg/m\^2 BID, days 1 to 14, oxaliplatin 130 mg/m\^2, day 1
Study NCT05702229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7789
Description: an anti PD 1 and anti TIM 3 bispecific antibody; IV infusion
Study NCT05702229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0901
Description: an anti Claudin18.2 ADC; IV infusion
Study NCT05702229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU, IV infusion, Q3W
Study NCT05702229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral take, Q3W
Study NCT06450314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuation of the anti-HER2 maintenance therapy
Description: Heroes is a de-escalation study. Patient must have received continuous anti-HER2 targeted therapy (including Trastuzumab, Trastuzumab/Pertuzumab, Trastuzumab-Deruxtecan, T-DM1) for at least 2 years in any line setting for their HER2-positive metastatic breast cancer with complete response or partial response at last radiological assessment. Patients with ctDNA negative test at baseline will stop their anti-HER2 targeted therapy during the study
Study NCT06450314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring with signatera test
Description: ctDNA test will be performed at 1.5 month after inclusion and every 3 months during 2 years.~Note: For the ctDNA negative patients who become ctDNA positive: ctDNA test will be performed once, 3 months after restarting treatment (+/-1 week).
Study NCT05771467 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive Ophthalmologic Examination
Description: Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters, optical coherence tomography angiography (OCTA)
Study NCT06492213 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: It is a observational study to investigate the efficacy and safety of PRP combined PRF on IONa compared to PRF alone.
Study NCT04095260 — intervention group
Intervention type: OTHER
Intervention: Pre-season strength and conditioning program
Description: The structured physical performance assessment will include functional movement testing, motor coordination testing, joint mobility screen, muscle strength testing, and agility performance testing. These measures will assess the effectiveness of pre-season strength and conditioning program to reduce musculoskeletal impairments and increase resistance to injury.
Study NCT06527664 — intervention group
Intervention type: DEVICE
Intervention: custom-made acetabular implant
Description: custom-made acetabular implant produced with additive manufacturing, to fill the bony loss in Paprosky III bone defects
Study NCT06392308 — intervention group
Intervention type: OTHER
Intervention: none intervention
Description: No interventions are administered to either group of patients.
Study NCT06379607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow High Flow Nasal Cannula
Description: High Flow Nasal Cannula will be applied in both experimental groups but different flow rates will be used in each arm; this arm will use higher flow rates.
Study NCT06379607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Flow High Flow Nasal Cannula
Description: High Flow Nasal Cannula will be applied in both experimental groups but different flow rates will be used in each arm; this arm will use lower flow rates.
Study NCT06582043 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SCARCr tester 1
Description: Twice daily
Study NCT06582043 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SCARCr tester 1
Description: Twice daily
Study NCT06582043 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Twice daily
Study NCT06178198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablative radioembolization using Yttrium-90 resin microspheres
Description: Based on 99mTc-MAA mapping, a partition model (multi-compartment MIRD) is employed to plan for a radiation dose of 400 (± 30%) to the tumor. If delivering this dose to the tumor is challenging due to lung dose limitations, the maximum feasible dose is administered to the tumor while maintaining the estimated lung dose below 15 Gy. While treating the entire tumor with a single high-dose radioembolization session is preferred, if necessary due to considerations like estimated lung dose, the treatment can be divided into two sessions, keeping the cumulative lung dose below 25 Gy. For any methods not covered in this discussion, refer to the SIR-Sphere user manual by Sirtex.
Study NCT04973826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam-Avibactam
Description: 500/167 mg ATM/AVI loading infusion, followed by 1500/500 mg ATM/AVI extended loading infusion, then 1500/500 mg ATM/AVI maintenance dose infusion every 6 hours
Study NCT06439992 — intervention group
Intervention type: DRUG
Intervention: 18F-Fluselenamyl
Description: Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan of the head and neck.
Study NCT05360576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSP-5415 (etonogestrel/ethinyl estradiol vaginal ring)
Description: To prevent pregnancy
Study NCT05360576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LSP-5415 (etonogestrel/ethinyl estradiol vaginal ring)
Description: To prevent pregnancy
Study NCT05360576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NuvaRing Vaginal Ring
Description: To prevent pregnancy
Study NCT05360576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuvaRing Vaginal Ring
Description: To prevent pregnancy
Study NCT05877781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Palmitoylethanolamide
Description: 8-week treatment 3x400 mg per day
Study NCT05877781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Palmitoylethanolamide
Description: 8-week treatment 3x400 mg per day
Study NCT05473767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check Up Heart
Description: Family Check-Up Heart consists of the Family Check up with an added heart health component. The Family Check-Up Heart assessment will include evaluations of maternal cardiovascular health; specifically, measurement of maternal blood pressure, body mass index, diet quality, exercise, and smoking, which will be included in the feedback session. After the Feedback Session participants will also receive information about healthy eating and weight loss, stress management, and smoking and to monitor weight and blood pressure.
Study NCT05473767 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Check-Up
Description: The Family Check-Up typically takes place over the course of 3-5 sessions, each about an hour long. First, a trained Family Check-Up family coach will conduct an Initial Interview. Second is an assessment of that includes questionnaires and videotaped interaction tasks. Third, during the Feedback Session, the family coach discusses with the participant strengths and challenges for their child and family as a whole. They then set goals for their family to support and maintain strengths, and to address any areas of concern. After the Feedback Session families have the option to continue meeting with their family coach to support the child's development and improve parental well-being.
Study NCT05106712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 4000IU per day for around 12 weeks.
Study NCT05106712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: oral Clomiphene citrate using its respective Stair-step dosage protocol as follow: 50 mg, 100 mg, and 150 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively.
Study NCT05106712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: oral Letrozole using its respective Stair-step dosage protocol as follow: 5 mg, 5 mg, and 7.5 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively, respectively.
Study NCT04570150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Subjects who are randomized to into the sugammadex arm (Arm I) will receive sugammadex for reversal of neuromuscular block at the completion of their anesthetic; Outcomes measures will be recorded and compared with those from Arm II (neostigmine group).
Study NCT04570150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neostigmine
Description: Subjects who are randomized into the neostigmine arm (Arm II) will receive neostigmine for reversal of neuromuscular block at the completion of their anesthetic; Outcomes measures will be recorded and compared with those from Arm I (sugammadex group).
Study NCT05106712 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: participants in the control (Placebo) group will be treated with equal amount of placebo tablets per day for the same duration
Study NCT06318169 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection
Study NCT06318169 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study NCT03692494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care voice therapy
Description: Exercises will include improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relaxation techniques to the neck and shoulder
Study NCT03692494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expiratory muscle strength training (EMST)
Description: EMST150 used at 75% of their maximum expiratory pressure. Participants will be directed to perform 5 sets of 5 breaths, 5 days per week, for 5 weeks, at the pressure threshold established in therapy. Maximum expiratory pressure will then be determined at the beginning of each therapy session and recalibration of the device will be performed if indicated.
Study NCT05604690 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avacc 10
Description: Intranasal application of either low dose or high dose of Covid 19 vaccine.
Study NCT05604690 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Outer Membrane Vesicles (OMV) : OMV alone in vehicle
Description: OMV will be administered via intranasal route.
Study NCT05604690 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via intranasal route.
Study NCT06372782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Skinboosters Vital Lidocaine
Description: Each subject will receive treatment on Day 1 with Restylane Skinboosters Vital Lidocaine in one hand and Restylane Vital in the opposite hand, as randomly assigned.
Study NCT06372782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Skinboosters Vital Lidocaine
Description: Each subject will receive treatment on Day 1 with Restylane Skinboosters Vital Lidocaine in one hand and Restylane Vital in the opposite hand, as randomly assigned.
Study NCT06372782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Vital
Description: Each subject will receive treatment on Day 1 with Restylane Vital in one hand and the experimental device in the opposite hand, as randomly assigned
Study NCT06372782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Vital
Description: Each subject will receive treatment on Day 1 with Restylane Vital in one hand and the experimental device in the opposite hand, as randomly assigned
Study NCT05180474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.
Description: GEN1047 will be administered as an intravenous infusion. The dose-levels will be determined by the starting dose and the escalation steps taken in the trial.
Study NCT06018129 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN3017
Description: Subcutaneous injection
Study NCT05718271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Explicit instructions before extinction
Description: Shocks will no longer be administered during the next phase.
Study NCT05718271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Explicit instructions after extinction
Description: Tomorrow no shocks will be administered.
Study NCT05148754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsulfavirine
Description: Elsulfavirin 200 mg tablets.
Study NCT05699798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative Treatment (CT)
Description: Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions.
Study NCT05699798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument-assisted Soft Tissue Mobilization (IASTM)
Description: IASTM was performed only on the neck and upper back muscles on the aching side using the sweep technique on the origo and insertion lines. A total of 6 sessions were applied, two sessions per week for 3 weeks.~Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions.
Study NCT05699798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Description: ESWT therapy was applied on the muscle with active trigger point, at 1.5-2.0 bar pressure, at 10 Hz frequency, 2000 beats in each session, twice a week, in total 6 sessions.~Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions.
Study NCT06466512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Midwifery-embodied care
Description: The midwife will provide ANC, delivery and PNC. The Community Healthcare Provider, Health Assistants will act as auxillary staff. Local transports will be integrated into the system. Coordination committee will see through that the interventions are carried out properly.
Study NCT04923022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegan Diet
Description: Participants with chronic neck pain who will be on a vegan diet will follow a diet program prepared by an expert dietitian under the supervision of an endocrinologist. In this diet program, a diet that includes grains, fruits, vegetables, legumes, as well as dairy products and eggs, known as lacto-ovo vegetarian, will be applied. Consumption of meat, poultry, fish, seafood and processed food and beverages will not be allowed. There will be no calorie restriction in the diet, and the diet will be arranged according to the amount of calories calculated by the expert dietitian according to BMI. The diet will last eight weeks. Individuals who follow a diet will be constantly checked by the workers with the mobile device application (My Fitness Pal®).
Study NCT04923022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Individuals in the therapeutic exercise group will perform therapeutic exercises for eight weeks, 3 days a week, accompanied by a specialist physiotherapist.
Study NCT05445557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RZL-012
Description: small synthetic molecule for submental fat reduction
Study NCT04867603 — intervention group
Intervention type: DRUG
Intervention: [Ga-68]PSMA
Description: The injectable activity will be a maximum of 210 MBq (6.0 mCi) \[Ga-68\]PSMA at the time of injection and is administered to subjects by intravenous injection.
Study NCT04867603 — intervention group
Intervention type: DEVICE
Intervention: PET/CT imaging
Description: PET/CT imaging procedure
Study NCT05445557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02659124 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AmnioFix plus Standard of Care
Description: Patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
Study NCT02659124 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care
Description: Patients will receive the standard of care dressing only, on their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
Study NCT06340815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Proton Therapy System (ProBeam)
Description: All enrolled subjects will be treated with Proton radiation therapy using the medical device Varian Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 2 weeks, while the treatment period depends on patient medical situation and treatment plan. The period after the last treatment is divided into short-term follow-up which is 90 days after treatment completion and long-term follow-up which is 5 years after treatment completion. The clinical trial with short-term follow-up fulfills the requirements for NMPA regulatory registration. All the end points claimed will be achieved in the short-term follow-up stage. The trial is defined as completion once short-term follow-up is finished.~And long-term follow-up report will be submitted for future post market evaluation when requested by NMPA.